Ventolin (albuterol) / GSK - LARVOL DELTA

Role of Salbutamol in the Management of Transient Tachypnea of the New Born (clinicaltrials.gov) - P1 | N=60 | Completed | Sponsor: Khyber Teaching Hospital

New P1 trial

A Comparative Study of Adding Ipratropium to Salbutamol for the Treatment of Asthma Attack in Children (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: Children's Hospital and Institute of Child Health, Multan

New P4 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Decarbonizing Respiratory Care: The Impact of a Low-carbon Salbutamol Metered-dose Inhaler (ATS 2025) - No abstract available

Late-breaking abstract

MITCHELL: A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma (clinicaltrials.gov) - P2 | N=102 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Evaluation of a cardboard-based spacer for enhancing aerosol delivery from pressurized metered dose inhalers. (PubMed, J Asthma) - "The in-vitro part evaluated salbutamol's aerodynamic particle size distribution (APSD) after 0, 20, 50, 120, and 200 uses of Ventolin pressurized metered dose inhaler (pMDI) when connected to MDI Plus using an Andersen cascade impactor at an inhalation flow of 28.3 L/min...The amount deposited on the MDI and the hands of the patients after multiple storage in the MDI Plus box and uses was insignificant and within the allowed limits. The MDI Plus simultaneously can act as an pMDI packaging box and spacer, serving as a practical, affordable, and accessible alternative to traditionally commercially available plastic spacers, particularly in resource-limited settings."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Correct use of inhalers for asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Drugs for asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Comparison chart: Some inhaled drugs for treatment of asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Pay to puff green: can NHS incentives change the prescribing practices? (BTS WM 2024) - "Comparator C2, involving salbutamol MDI swaps (mainly Ventolin to Salamol), showed significant improvement, with 8.11 new inhalers prescribed per 1,000 patients...When the inhaler swap did not necessitate introducing a new device and patient education (C2), the incentive was more effective. Despite the equal availability of the incentive, its uptake varied across England, potentially due to differences in guidelines and formularies ( figure 1 )."

Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Usability testing of a 3D-printed assistive device adaptor for a pressurized metered-dose inhaler (APSR 2024) - "Gripping force(s) required to depress the canister has significantly reduced by 73.5% (3.39kgfÀ0.90kgf) and 69.6% (2.73kgfÀ0.83kgf) for Ventolin and Atrovent respectively using Newton meter... 3D printed puff adaptors were effective in aiding patients with hand deficits in administering puffs."

Chronic Obstructive Pulmonary Disease • Immunology • Inflammatory Arthritis • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology

Comparison of 3% Hypertonic Saline and Salbutamol in Children With Bronchiolitis (clinicaltrials.gov) - P=N/A | N=100 | Not yet recruiting | Sponsor: University of Health Sciences Lahore

New trial • Pulmonary Disease • Respiratory Diseases

MITCHELL: A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma (clinicaltrials.gov) - P2 | N=102 | Not yet recruiting | Sponsor: AstraZeneca

New P2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

VALUE OF CHEST PHYSIOTHERAPY WITH CONTINUOUS POSITIVE AIRWAY PRESSURE IN 5-YEAR-OLD CHILDREN: EFFECTS ON ATELECTASIS IN AMBULATORY HOSPITAL CARE (CHEST 2024) - "After one month of hospitalization in intensive care, she finally left the hospital with an inhaled treatment (Axotide, Ventolin) but remained short of breath and tired... A respiratory physiotherapy adapted to continuous positive airway pressure can significantly reduce atelectasis firmly established for many months in a young child."

Clinical • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Pulmonary Disease • Respiratory Diseases

PRISM: Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma (clinicaltrials.gov) - P4 | N=100 | Completed | Sponsor: GlaxoSmithKline | Recruiting ➔ Completed

Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Inhalation through two mini-spacer-like inhaler technique training devices: An in-vitro aerosol delivery comparative study (ERS 2024) - " 30 and 90 L/min inhalation flow rates over 2 and 5 sec were used to compare aerosol delivery of salbutamol from Ventolin Evohaler connected to FT and FTCR... The FT and FTCR delivered comparable salbutamol doses and fine particles (≤5 µm) under optimal and suboptimal inhalation through pMDI. The FTCR was privileged with lower throat deposition. Ultimately, these devices are intended to improve and maintain patients' correct pMDI use."

Preclinical • Respiratory Diseases

Does Use Of A Heat and Moisture Exchanger Affect pMDI Delivery to a Simulated Patient on Mechanical Ventilation (ERS 2024) - "5 actuations of Ventolin pMDI were delivered through 3 different delivery devices and a built-in port adapter in the circuit, followed by 6 complete breathing cycles... This study has shown that use of a bypass-type HME can allow delivery of medication to the patient. It also demonstrates that use of AeroChamber* VENT HC spacer could potentially reduce the carbon footprint by up to 4-fold compared to the alternative options. By maximizing the amount of each puff reaching the lungs the patient is likely to get relief sooner and reduce the number of puffs needed."

Clinical • Critical care • Respiratory Diseases

Drugs for COPD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tobacco Cessation

Projected Savings on Inhalers Purchased Via Mark Cuban Cost Plus Drug Company (MCCPDC) Versus Medicare Part-D (ATS 2024) - "Top Pulmonology inhalers studied were Albuterol Sulfate (Ventolin), Albuterol Sulfate (Proair), Albuterol sulfate (Proventil), Albuterol Sulfate HFA, Fluticasone Salmeterol (Advair Diskus) and Fluticasone Salmeterol (Advair HFA). Purchasing prescription drugs through MCCPDC showed substantial potential cost-savings for pulmonology directed rugs. MCCPDC could be a reasonable financial alternative for Medicare Part D spending on pulmonology drugs to reduce the financial burden of healthcare related costs."

Medicare • Reimbursement • US reimbursement • Alpha-1 Antitrypsin Deficiency • Chronic Obstructive Pulmonary Disease • Critical care • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Performance of a Portable Spacer Compared to the Metered Dose Inhaler Alone and a Commonly Recommended Spacer (ATS 2024) - "5 actuations of Ventolin® or Atrovent® were delivered at 30s intervals to the device on test and the active pharmaceutical ingredient recovered from the CI was assayed by HPLC... These in vitro data provide guidance to the clinician that the new AeroChamber2go™ spacer provides only slightly lower fine particle dose (FPD) performance than the full-size standard spacer and similar FPD to that of the pMDI alone. Given the known real life coordination challenges using a pMDI alone, which may be even worse in a rescue situation, the portable spacer provides a more convenient alternative for those patients who currently do not use a spacer 'On the Go'."

Alpha-1 Antitrypsin Deficiency • Asthma • Chronic Obstructive Pulmonary Disease • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Airsupra: An inhaled albuterol/budesonide combination for asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Warren rebukes GSK for alleged 'money grab' after company pulled popular asthma med (Fierce Pharma) - "After removing Flovent HFA from the market, GSK and its partner substituted an authorized generic version with a lower list price—currently around $310—compared to the branded product’s $340...The spokesperson explained that GSK elected to launch authorized generics for Flovent HFA and its sister product Flovent Diskus to help maintain patient access to the drug, potentially at a lower cost...GSK in December removed four patents related to its inhaler products Advair, Annuity, Flovent and Ventolin from the FDA’s Orange Book following the U.S. Federal Trade Commission’s (FTC’s) recent crackdown on 'improper' listings."

Discontinued • Patent • Pricing • Asthma

Role of Parasympathetic Activity in Mild to Severe Asthma With Fixed Airway Obstruction (PARASMA Study) (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Hat Yai Medical Education Center | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

DOES SPACER/ADAPTER DEVICE CHOICE AFFECT DELIVERY OF A PRESSURIZED METERED DOSE INHALER (PMDI) THROUGH A HUMIDIFIED CIRCUIT TO A SIMULATED PATIENT ON MECHANICAL VENTILATION (BTS WM 2023) - "5-actuations of a Ventolin† pMDI were delivered through the device on test, each time followed by 6-complete breathing cycles, shaking the canister between actuations...Although Spirale† DDS closely resembles AeroChamber* VENT HC (also marketed as AeroVent Plus* Collapsible Holding Chamber), the Spirale† bellows had difficulties keeping a spacer-like shape when expanded for aerosol delivery. This study highlights the variability in drug delivery using a pMDI and that spacer/adapter choice are critical factors to be considered when using these devices as a treatment option."

Clinical • Infectious Disease

WHAT PROGRESS HAS BEEN MADE IN REDUCING GREENHOUSE GAS EMISSIONS FROM INHALERS IN ENGLAND? AN ANALYSIS OF INHALER PRESCRIBING DATA 2018–2023 (BTS WM 2023) - "Some MDIs have lower carbon footprints than others, for example lowvolume Salbutamol inhalers (Salamol, Airomir) have lower carbon footprint than high-volume (Ventolin Evohaler)...Conclusions Carbon emissions from the highest carbon inhalers appears to have reduced. Further efforts are needed_x000D_to increase use of low-carbon controller therapy, which could_x000D_reduce the footprint of controller therapies, whilst also importantly improving disease control and reducing the need for_x000D_SABA inhalers and related emissions."

Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Mechanisms for Dyspnea on Exertion in Children With Obesity and Asthma: Distinct Physiological Phenotypes (clinicaltrials.gov) - P4 | N=0 | Withdrawn | Sponsor: Ohio State University | N=48 ➔ 0 | Trial completion date: Nov 2028 ➔ Nov 2023 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Nov 2027 ➔ Nov 2023

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Asthma • Genetic Disorders • Immunology • Obesity • Pulmonary Disease • Respiratory Diseases